Athira Pharma, Inc. (ATHA)
NASDAQ: ATHA · Real-Time Price · USD
0.2800
+0.0100 (3.70%)
At close: May 13, 2025, 4:00 PM
0.2716
-0.0084 (-3.00%)
Pre-market: May 14, 2025, 8:12 AM EDT
Athira Pharma Employees
Athira Pharma had 26 employees as of December 31, 2024. The number of employees decreased by 41 or -61.19% compared to the previous year.
Employees
26
Change (1Y)
-41
Growth (1Y)
-61.19%
Revenue / Employee
n/a
Profits / Employee
-$3,067,154
Market Cap
10.93M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 26 | -41 | -61.19% |
Dec 31, 2023 | 67 | 3 | 4.69% |
Dec 31, 2022 | 64 | 29 | 82.86% |
Dec 31, 2021 | 35 | 13 | 59.09% |
Dec 31, 2020 | 22 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ATHA News
- 22 hours ago - Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit - GlobeNewsWire
- 4 days ago - Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates - GlobeNewsWire
- 2 months ago - Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates - GlobeNewsWire
- 4 months ago - Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct - GeekWire
- 5 months ago - Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND - GlobeNewsWire
- 6 months ago - Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates - GlobeNewsWire
- 8 months ago - Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring - GeekWire
- 8 months ago - Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - GlobeNewsWire